Evommune, Inc.
No enriched coverage for $EVMN in the last 7 days.
No SEC Form 4 filings for $EVMN in the last 30 days.
See all $EVMN insider activity →Evommune's (EVMN) stock fell 53% after its eczema treatment failed midstage trials, following a previous failure in treating hives. The company continues testing EVO756 for migraine prevention and has another eczema treatment, EVO301, in development.
US equity futures fell as Brent crude oil topped $100, pushing 10-year Treasury yields above 4.81%. Meta (META) rose 5% on strong AI usage, while other Mag 7 stocks traded mixed. Braze (BRZE) dropped 11% on weak earnings forecasts, and ServiceTitan (TTAN) fell 17% on revenue concerns. Chime (CHYM) gained 9% after acquiring Stride Bank. Oil prices surged after US strikes on Iranian tankers, and Treasury Secretary Scott Bessent challenged traders on yen strength. Barclays raised its S&P 500 target
Evommune Inc (EVMN) shares dropped 27% after its EVO756 drug failed to meet primary and secondary endpoints in a Phase 2b trial for atopic dermatitis. The trial involved 121 adults over 12 weeks. Evommune will not advance EVO756 for this indication but will continue its development for migraine prophylaxis. The company plans to advance EVO301 for atopic dermatitis, with a Phase 2b trial expected in mid-2027. Evommune reports a strong balance sheet supporting operations into 2029.
Recent EVMN coverage spans financial news, market movers and insider activity.
Negative trial outcome likely pressures the share price further.
Clinical failure reduces near‑term pipeline value.
The negative trial data is likely to push the stock lower in the short term.
New coverage may attract investors and lift price toward target.
Near-term catalyst is September 2026 AD Phase 2b top-line data for EVO756; longer-dated catalysts include migraine Phase 2b top-line in 2027 and EVO301 Phase 2a conference presentation.
AlphAI scores every news story that mentions EVMN with an AI model for sentiment and relevance, and aggregates insider trades from Evommune, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Evommune's (EVMN) stock fell 53% after its eczema treatment failed midstage trials, following a previous failure in treating hives. The company continues testing EVO756 for migraine prevention and has another eczema treatment, EVO301, in development.
1 min readUS equity futures fell as Brent crude oil topped $100, pushing 10-year Treasury yields above 4.81%. Meta (META) rose 5% on strong AI usage, while other Mag 7 stocks traded mixed. Braze (BRZE) dropped 11% on weak earnings forecasts, and ServiceTitan (TTAN) fell 17% on revenue concerns. Chime (CHYM) gained 9% after acquiring Stride Bank. Oil prices surged after US strikes on Iranian tankers, and Treasury Secretary Scott Bessent challenged traders on yen strength. Barclays raised its S&P 500 target
3 min readEvommune Inc (EVMN) shares dropped 27% after its EVO756 drug failed to meet primary and secondary endpoints in a Phase 2b trial for atopic dermatitis. The trial involved 121 adults over 12 weeks. Evommune will not advance EVO756 for this indication but will continue its development for migraine prophylaxis. The company plans to advance EVO301 for atopic dermatitis, with a Phase 2b trial expected in mid-2027. Evommune reports a strong balance sheet supporting operations into 2029.
2 min readAnalysts initiated coverage on several companies: Needham rated Evommune (EVMN) Buy with a $28 target, Daiwa rated ACM Research (ACMR) Buy with a $136 target, Wolfe Research rated Harmony Biosciences (HRMY) Outperform with a $60 target, RBC rated Atlassian (TEAM) Outperform with a $215 target, and RBC rated JFrog (FROG) Outperform with a $118 target.
2 min readEvommune, Inc. (EVMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in
4 min readCarver Kyle (Chief Financial Officer) purchased 1,000 shares of Evommune, Inc. (EVMN) at $13.26 on 2026-07-08.
1 min readA roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
7 min readKIRSCH ARTHUR S purchased 10,000 indirectly-held shares of Evommune, Inc. (EVMN) at $13.30 ($0.13M total) on 2026-07-07.
2 min readLevi & Korsinsky said it is investigating Evommune, Inc. (NYSE: EVMN) after its lead drug EVO756 failed a Phase 2b primary endpoint, which the company said led to about a 38% share drop. The firm cites CEO Luis Pena and CSO Jeegar Patel sales/exercises on June 22, 2026 under Rule 10b5-1 plans before the disclosure.
5 min readA roundup of analysts’ June 30 price-target changes across many stocks. Examples: Wells Fargo raised AAL to $17 from $12; Leerink raised ABVX to $148 from $140; JPMorgan cut ACI to $20 from $22; Jefferies cut ALB to $211 from $244; Goldman cut APA to $32 from $34; KeyCorp raised ATI to $211 from $175.
2 min read
